Bull & Bear

Bull and Bear

Verdict: Lean Long, Wait For Confirmation — Q1 FY26 Medicaid HBR improved 50 bp YoY to 93.1% (consolidated HBR 87.3%) and operating cash flow held at $5.1B through a $6.7B GAAP loss, but management's own FY26 consolidated guide (90.9–91.7%) does not recover to pre-2025 levels. The decisive variable is whether the next two quarters extend the HBR repricing trend or stall with consolidated HBR above 91%. Balance sheet ($2.9B net cash, $1B notes retired) removes existential risk, which sets up an asymmetric setup if the bull's normalization path holds. The single most contested point is whether the FY25 loss was a cyclical mismatch or a structural margin reset; one quarter of improvement is consistent with both reads. The condition that would change the conclusion is a re-spike in consolidated HBR above 91% in Q2 or Q3 FY26 with no rate catch-up in top-five Medicaid states.

Bull Case

Bull target: $80 in 12–18 months, derived from 15x normalized EPS of $5.30 (return to 4–5% operating margin and 10% ROE). Primary catalyst is Q2 FY26 earnings (July 28) confirming consolidated HBR holds below 90% with Medicaid HBR continuing sequential improvement off the 93.1% Q1 print. Disconfirming signal: consolidated HBR re-spikes above 91% in Q2 or Q3 FY26.

Bear Case

Bear downside: $41 in 12–18 months, blended from a tangible-book floor and ~30% multiple compression on normalized ~$3.00 EPS (~$42). Primary trigger: Q3 FY26 earnings showing consolidated HBR above 91% with no rate catch-up in top-five Medicaid states. Cover signal: two consecutive quarters of consolidated HBR trending into the high 80s with composite Medicaid rate growth above 5%.

The Real Debate

Verdict

Lean Long, Wait For Confirmation. Bull carries more weight on the strength of two anchors the bear cannot dismantle: operating cash flow of $5.1B that ran straight through a $6.7B GAAP loss, and a Q1 FY26 Medicaid HBR print that moved in the right direction by 50 bp (to 93.1%, with consolidated HBR at 87.3%). The single most important tension is whether the HBR trajectory is cyclical repricing or a structural step-up — management's own FY26 consolidated guide of 90.9–91.7% genuinely does not return to pre-2025, which is the bear's hardest point and remains unresolved by one quarter of data. The bear could still be right if Marketplace morbidity does not normalize post-APTC and Medicaid rate negotiations in the 30-state portfolio fail to close the 100–150 bp acuity gap, in which case normalized ROE caps at 8–9% and the multiple compresses, not expands. The condition that flips the verdict to Lean Long with full conviction is two sequential quarters of consolidated HBR trending toward the high 80s with composite Medicaid rate growth at or above 4.5–5%; the condition that flips it to Avoid is a re-spike of consolidated HBR above 91% in Q2 or Q3 FY26 with no rate catch-up. This is a setup that rewards patience over conviction at this snapshot.